Records containing: Mantle Cell Lymphoma (MCL)
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-09-19Application of the Autologous CAR T Cells (Tarcidomgen Kimleucel) in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
-
CLINICAL_TRIALS study record update · 2024-08-21A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas
-
CLINICAL_TRIALS study record update · 2024-07-18A Phase I/II Study to Evaluate the Safety and Efficacy of the MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
-
CLINICAL_TRIALS study record update · 2024-07-11A Multicenter, Open-label, Randomized Controlled Study of Orelabrutinib in Combination With Bendamustine and Rituximab Versus Bendamustine and Rituximab in the Treatment of Transplant-Ineligible, Intermediate- to High-Risk Mantle Cell Lymphoma (MCL)
-
CLINICAL_TRIALS study record update · 2024-03-22A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-07-11A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 Administered in Subjects With Non-Hodgkin's Lymphoma
-
CLINICAL_TRIALS study record update · 2023-05-09A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL
-
CLINICAL_TRIALS study record update · 2022-12-14Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
-
CLINICAL_TRIALS study record update · 2022-06-06A Multicenter Prospective Observational Study to Evaluate the Safety and Efficacy of Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
-
CLINICAL_TRIALS study record update · 2022-05-06A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
-
CLINICAL_TRIALS study record update · 2021-06-28REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS
-
CLINICAL_TRIALS study record update · 2021-02-23A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T Cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
-
CLINICAL_TRIALS study record update · 2018-10-19An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
-
CLINICAL_TRIALS study record update · 2017-08-29Evaluation of Peripheral Blood (PB) Immunophenotyping in the Detection of Bone Marrow Involvement in Cases of Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).